Compounded Semaglutide vs Wegovy: Are They the Same?

Same Molecule, Very Different Prices

When patients learn that compounded semaglutide costs 70–80% less than Wegovy, the first question is almost always: "Is it really the same thing?" The answer is nuanced but fundamentally reassuring. Compounded semaglutide and Wegovy contain the same active molecule — semaglutide — which works through identical mechanisms in the body. The differences lie in how they are manufactured, regulated, and priced.

Wegovy is a finished pharmaceutical product manufactured by Novo Nordisk in large-scale GMP (Good Manufacturing Practice) facilities, subjected to FDA review and approval as a specific drug product. Compounded semaglutide is prepared by licensed compounding pharmacies using pharmaceutical-grade semaglutide API (active pharmaceutical ingredient), under different but still legally regulated conditions.

For a complete safety overview of compounded options, see our compounded semaglutide safety guide. If you want to understand pricing in detail, our semaglutide cost breakdown covers every option.

Side-by-Side Comparison

Is Compounded Semaglutide Legal?

Yes — with important caveats. FDA law allows compounding pharmacies to prepare copies or variations of FDA-approved drugs under specific conditions. One of those conditions is when a drug appears on the FDA's Drug Shortage List. Semaglutide (Wegovy) was on the shortage list from 2022 through much of 2025, which created the legal pathway that allowed compounded semaglutide to flourish.

In early 2025, the FDA removed semaglutide from its shortage list — a development that created uncertainty in the market. However, many providers and pharmacies continued to offer compounded semaglutide under Section 503A (patient-specific compounding) and Section 503B (outsourcing facilities), which remain legal avenues under different criteria than shortage-based compounding.

For the most up-to-date analysis of regulatory status, see our article on FDA compounding regulations in 2026. Trimi's pharmacies operate under the appropriate regulatory framework and Trimi's medical team stays current on all FDA guidance.

The Cost Case for Compounded Semaglutide

The financial difference is staggering. At Wegovy's list price of $1,100–$1,349 per month, a year of treatment costs $13,200–$16,188. Most commercial insurance plans still do not cover Wegovy for weight loss alone, making out-of-pocket costs prohibitive for most patients.

Compounded semaglutide through a program like Trimi runs $200–$400 per month, including the medication and medical supervision. Over a full year, that's $2,400–$4,800 — a savings of $8,000–$11,000 compared to brand-name Wegovy. For many patients, this price difference is the entire difference between accessing treatment or going without.

See our full Trimi pricing and subscription guide for a complete breakdown of program costs.

What to Watch Out For

Not all compounded semaglutide is equal. Quality varies significantly depending on the pharmacy's standards, testing protocols, and regulatory compliance. There have been reports of semaglutide acetate (a chemically distinct form not used in any FDA-approved drug) being sold as compounded semaglutide. This is a concern: semaglutide acetate has not been validated for human use and is not the same as the semaglutide sodium or semaglutide free base used in clinical trials and FDA-approved products.

When evaluating a compounded semaglutide provider, ask: Is the pharmacy 503B registered? Does it use semaglutide free base or sodium (not acetate)? Does it provide Certificates of Analysis for each batch? Is there a licensed physician providing ongoing medical oversight? Trimi's quality and compliance standards address each of these requirements.

Clinical Outcomes: What to Expect

Because compounded semaglutide contains the same active molecule as Wegovy, the landmark STEP clinical trial results are directly applicable. STEP 1 showed 14.9% average body weight reduction over 68 weeks at 2.4mg weekly dosing. STEP 4 showed that patients who maintained semaglutide continued losing weight while those who stopped regained 70% of the weight within a year — underscoring the importance of ongoing treatment.

Real-world outcomes from compounded programs closely mirror clinical trial data when patients follow the same dose escalation protocol and maintain lifestyle modifications. For detailed information on what to expect month by month, see our semaglutide results timeline and our guide on semaglutide before and after results.